Cargando…
Response to effect estimation of hydroxychloroquine for COVID-19: a secondary analysis of an open label non-randomized clinical trial.
Autores principales: | Gautret, Philippe, Hoang, Van Thuan, Lagier, Jean-Christophe, Raoult, Didier |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd and International Society of Antimicrobial Chemotherapy.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7779261/ https://www.ncbi.nlm.nih.gov/pubmed/33408027 http://dx.doi.org/10.1016/j.ijantimicag.2020.106237 |
Ejemplares similares
-
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial revisited
por: Gautret, Philippe, et al.
Publicado: (2021) -
Effect of hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, an update with an intention-to-treat analysis and clinical outcomes
por: Gautret, Philippe, et al.
Publicado: (2021) -
Clinical efficacy and safety profile of hydroxychloroquine and azithromycin against COVID-19
por: Gautret, Philippe, et al.
Publicado: (2021) -
Response to uncertain effect of hydroxychloroquine and azithromycin on SARS-CoV-2 viral load.
por: Gautret, Philippe, et al.
Publicado: (2021) -
Response to the use of hydroxychloroquine in combination with azithromycin for patients with COVID-19 is not supported by recent literature.
por: Gautret, Philippe, et al.
Publicado: (2021)